Duchenne Muscular Dystrophy (Duchenne)

«We are proud to serve the rare diseases community, and honoured that we are able to contribute to the global mission to find new solutions for Duchenne»

Francesco De Santis, Chairman of ITALFARMACO

What is Duchenne?

Duchenne muscular dystrophy is a rare neuromuscular disorder, characterised by progressive muscle damage and weakness. It occurs almost exclusively in males due to its X-linked recessive genetic pattern. Duchenne Muscular Dystrophy (DMD) is a condition that knows no borders, with an estimated incidence of 1 in 5,000 male newborns worldwide. In 2023, the Dutch Dystrophinopathy Database (DDD) registered 524 individuals with DMD, including 44 females carrying a pathogenic variant in the DMD gene. Although girls are not typically affected, they can be carriers of the genetic mutation and may present symptoms of what is known as a dystrophinopathy.1-3

Duchenne is caused by mutations in the dystrophin gene resulting in an absence or non-functional dystrophin, a key structural protein protecting the muscle cells from repeated contraction-induced damage.4

How does Duchenne affect the body?

For individuals with Duchenne, their muscles are under constant siege, vulnerable to damage from everyday activities. A normal healthy muscle can counteract muscle damage thanks to its inner capability to regenerate new muscle cells. However, the muscles of people affected by Duchenne are more susceptible to injury and their muscle regeneration is impaired. The body naturally tries to repair the damage, but continuous muscle fibre damage leads to chronic inflammation, and the muscle fibres are replaced by scaring (fibrous tissue) and fat deposits. Over time, the muscles lose their capability to regenerate and their ability to contract, resulting in loss of muscle mass and weakness. It can be a relentless battle that families and doctors face together.5–8

Living with Duchenne

Across the globe, from Europe to the United States and beyond, individuals from the Duchenne community share stories of resilience and hope:

«It’s good to remember that most Duchenne children are happy kids and most families do very well after the initial shock of the diagnosis.»

Elizabeth Vroom, World Duchenne Organization (UPPMD)
The diagnosis and management of Duchenne Muscular Dystrophy – A guide for Families

«Once we received a definitive diagnosis, we could finally name our struggle. Hope is always present because we work tirelessly day by day towards a future without Duchenne.»

Silvia Avila, President – Duchenne Parent Project (DDP) – Spain

«When the word Duchenne came into our lives, 10 years ago, it was a shock, I couldn’t even pronounce it. Slowly we realized that we could walk alongside each other, that there are ways forward in this coexistence thanks to a community of families ready to share experiences and to an international scientific community whose studies give hope.»

Mother of a Duchenne child, Parent Project – Italia

What are the signs and symptoms of Duchenne?

Learn more about what to expect as Duchenne progresses

Useful Links

The rare disease and Duchenne community focus on raising awareness and facilitating connections between families, providing resources related to education, research, and support services. Here are just a few regional and global patient organisations and charities where you will find further useful information and connections.

Duchenne Parent Project Netherlands

Funds research, promotes awareness, and supports families affected by Duchenne muscular dystrophy, aiming for better treatment and ultimately a cure.

Spierziekten Nederland

Provides information, advocacy, and peer support for people with neuromuscular diseases to improve quality of life and access to care.

Duchenne Centrum Nederland

Brings together top clinical expertise and cutting-edge research to optimize care and accelerate the search for a cure for Duchenne muscular dystrophy.

Cure Duchenne

Specifically focused on Duchenne muscular dystrophy, this site offers information about the disease, treatments, research, and support for affected families.

Duchenne Data Foundation

DDF brings together all sources of data related to dystrophinopathies, to make an impact for the global DMD community.

EURO-NMD

European Reference Network for Neuromuscular Diseases.

EURORDIS (Rare Diseases Europe)

Working to improve the quality of life for people living with rare diseases in Europe. It offers educational resources, participation opportunities, and community support.

Rare Diseases International (RDI)

Rare Diseases International is the global alliance of people living with a rare disease of all nationalities across all rare diseases.

World Duchenne Organisation

The World Duchenne Organization is a global umbrella organization of national patient organizations. Dedicated to finding a cure and viable treatments for DMD, promoting good standards of care, to inform parents and people living with the condition around the globe.

1. Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, and al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79.

2. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71(3):304-13.

3. NM van de Velde and al. The Dutch Dystrophinopathy Database: A National Registry with Standardized Patient and Clinician Reported Real-World Data. J Neuromuscul Dis. 2024 Sep 3;11(5):1095–1109.

4. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-67.

5. Theret M, Rossi FMV, Contreras O. Evolving Roles of Muscle-Resident Fibro-Adipogenic Progenitors in Health, Regeneration, Neuromuscular Disorders, and Aging. Front Physiol. 2021;12:673404.

6. Giuliani G, Rosina M, Reggio A. Signaling pa thways regulating the fate of fibro/adipogenic progenitors (FAPs) in skeletal muscle regeneration and disease. FEBS J. 2022;289(21):6484-6517.

7. Lemos DR, Babaeijandaghi F, Low M, Chang CK, L ee ST, Fiore D, and al. Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/ adipogenic progenitors. Nat Med. 2015;21(7):786-94.

8. Chapman MA, Mukund K, Subramaniam S, Brenner D, Lieber RL. Three distinct cell populations express extracellular matrix proteins and increase in number during skeletal muscle fibrosis. Am J Physiol Cell Physiol. 2017;312(2):C131–43.